ArticleCureus2026
Atypical Vesicular Skin Eruption Following a Low-Dose Methotrexate Dosing Error: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate is widely used to manage various autoimmune conditions, including psoriasis and psoriatic arthritis. Although weekly low-dose regimens are generally well-tolerated, dosing errors, particularly daily instead of weekly administration, can result in acute methotrexate toxicity with mucocutaneous and hematologic complications. We present a case of clinically significant methotrexate toxicity manifesting with painful oral mucositis and vesicular cutaneous lesions on the right lateral abdomen and right supraclavicular region in a 68-year-old Caucasian female patient with psoriasis and psoriatic arthritis after inadvertently taking 15 mg of methotrexate daily for five consecutive days (75 mg cumulative) instead of her prescribed weekly 15 mg dose. The patient was admitted for intravenous hydration with sodium bicarbonate and leucovorin 200 mg every six hours, then transitioned to oral leucovorin for an additional 48 hours on discharge. Mucosal symptoms gradually resolved during her four-day admission, no new skin lesions developed after hospital day 2, and laboratory values trended toward normalization without clinically significant myelosuppression, neutropenia, thrombocytopenia, or hepatorenal injury. This case illustrates that an inadvertent daily-instead-of-weekly dosing error can produce clinically significant mucocutaneous toxicity, and that prompt recognition with leucovorin rescue may help limit progression to the myelosuppression and systemic complications that can accompany methotrexate toxicity. It is important for clinicians to remain vigilant for toxic adverse effects to prevent progression to life-threatening complications and enhance patient education to avoid dosing errors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.